$1.2
Live
0.0%
Downside
Day's Volatility :4.75%
Upside
4.75%
15.83%
Downside
52 Weeks Volatility :81.33%
Upside
77.82%
Period | Alterity Therapeutics Ltd | Index (Russel 2000) |
---|---|---|
3 Months | -26.32% | 0.0% |
6 Months | -40.85% | 0.0% |
1 Year | -53.33% | 0.0% |
3 Years | -90.16% | -23.0% |
Market Capitalization | 10.5M |
Book Value | $0.00 |
Earnings Per Share (EPS) | -2.1 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -612.91% |
Return On Assets TTM | -52.66% |
Return On Equity TTM | -104.47% |
Revenue TTM | 4.0M |
Revenue Per Share TTM | 0.6 |
Quarterly Revenue Growth YOY | 38.4% |
Gross Profit TTM | 3.6M |
EBITDA | -19.6M |
Diluted Eps TTM | -2.1 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.22 |
EPS Estimate Next Year | -0.09 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 483.33%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 75.4K | ↓ 46.05% |
Net Income | -8.6M | ↑ 49.26% |
Net Profit Margin | -11.4K% | ↓ 7258.54% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 283.9K | ↑ 279.19% |
Net Income | -6.9M | ↓ 18.46% |
Net Profit Margin | -2.4K% | ↑ 8923.05% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 2.5M | ↑ 690.65% |
Net Income | -11.7M | ↑ 52.19% |
Net Profit Margin | -470.47% | ↑ 1973.77% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.5M | ↑ 8.71% |
Net Income | -9.0M | ↓ 16.08% |
Net Profit Margin | -363.18% | ↑ 107.29% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.8M | ↓ 26.26% |
Net Income | -9.3M | ↑ 7.47% |
Net Profit Margin | -529.3% | ↓ 166.12% |
FY24 | Y/Y Change | |
---|---|---|
Revenue | 1.8M | ↑ 2.78% |
Net Income | -8.3M | ↓ 9.24% |
Net Profit Margin | -467.42% | ↑ 61.88% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 548.1K | ↑ 6.44% |
Net Income | -1.8M | ↑ 6.44% |
Net Profit Margin | -336.65% | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 410.4K | - |
Net Income | -1.4M | - |
Net Profit Margin | -342.35% | - |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 690.7K | - |
Net Income | -4.1M | ↓ 3.12% |
Net Profit Margin | -595.51% | - |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 706.6K | ↑ 2.29% |
Net Income | -8.3M | ↑ 101.87% |
Net Profit Margin | -1.2K% | ↓ 579.67% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 13.8M | ↑ 6.32% |
Total Liabilities | 2.3M | ↑ 26.86% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 9.2M | ↓ 33.17% |
Total Liabilities | 1.9M | ↓ 17.83% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 25.6M | ↑ 152.43% |
Total Liabilities | 2.4M | ↑ 13.0% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 29.1M | ↑ 23.16% |
Total Liabilities | 4.1M | ↑ 89.2% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 18.4M | ↓ 33.96% |
Total Liabilities | 3.0M | ↓ 23.57% |
FY24 | Y/Y Change | |
---|---|---|
Total Assets | 12.8M | ↓ 29.63% |
Total Liabilities | 3.6M | ↑ 20.44% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 22.5M | ↑ 56.35% |
Total Liabilities | 3.6M | ↑ 57.77% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 9.6M | ↓ 57.26% |
Total Liabilities | 2.0M | - |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 22.2M | ↑ 55.56% |
Total Liabilities | 4.6M | ↑ 55.56% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 12.5M | ↓ 43.52% |
Total Liabilities | 3.5M | ↓ 22.57% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 12.8M | ↑ 53.36% |
Total Liabilities | 3.6M | ↑ 53.36% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.7M | ↑ 123.45% |
Investing Cash Flow | -4.9K | ↓ 61.87% |
Financing Cash Flow | 8.8M | ↓ 11915.14% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -6.5M | ↓ 32.42% |
Investing Cash Flow | -11.5K | ↑ 138.45% |
Financing Cash Flow | 2.7M | ↓ 68.7% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.2M | ↑ 83.75% |
Investing Cash Flow | -8.0K | ↓ 37.46% |
Financing Cash Flow | 28.1M | ↑ 823.89% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -8.7M | ↓ 28.81% |
Investing Cash Flow | -62.7K | ↑ 751.29% |
Financing Cash Flow | 11.6M | ↓ 54.98% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.5M | ↑ 62.64% |
Investing Cash Flow | -24.5K | ↓ 59.1% |
Financing Cash Flow | 119.6K | ↓ 98.93% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.6M | ↑ 15.56% |
Investing Cash Flow | -10.5K | ↑ 547.48% |
Financing Cash Flow | 83.5K | ↓ 214.79% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 368.8K | ↓ 114.06% |
Investing Cash Flow | -10.6K | ↑ 0.0% |
Financing Cash Flow | -11.4K | ↓ 113.6% |
Sell
Neutral
Buy
Alterity Therapeutics Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Alterity Therapeutics Ltd | 1.61% | -40.85% | -53.33% | -90.16% | -88.44% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Alterity Therapeutics Ltd | NA | NA | NA | -1.22 | -1.04 | -0.53 | NA | 0.0 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Alterity Therapeutics Ltd | NA | $10.5M | -88.44% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Alterity Therapeutics Ltd
Revenue is up for the last 3 quarters, 610.92K → 706.56K (in $), with an average increase of 6.9% per quarter
Netprofit is down for the last 2 quarters, -4.11M → -8.30M (in $), with an average decrease of 101.9% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 130.8%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 135.0%
Morgan Stanley - Brokerage Accounts
Susquehanna International Group, LLP
Twin Lakes Capital Management, LLC
alterity therapeutics limited researches and develops therapeutic drugs for the treatment of parkinsonian's disease and other neurodegenerative diseases in australia. the company's lead drug candidates is ath434 that has completed phase i clinical trial for the treatment of parkinson's disease. it is also developing pbt2 for used as an antimicrobial agent. the company was formerly known as prana biotechnology limited and changed its name to alterity therapeutics limited in april 2019. the company was founded in 1997 and is based in melbourne, australia.
Organization | Alterity Therapeutics Ltd |
Employees | 10 |
CEO | Mr. Geoffrey Paul Kempler B.Sc. |
Industry | Biotechnology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$1.20
-4.76%
Invesco Bulletshares 2025 Hi
$1.20
-4.76%
Schwab International Dividend Equity Etf
$1.20
-4.76%
Blockchain Coinvestors Acquisition Corp.
$1.20
-4.76%
Allgiant Travel Company
$1.20
-4.76%
Rogers Corp
$1.20
-4.76%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$1.20
-4.76%
Iheartmedia
$1.20
-4.76%
Lightpath Technologies Inc
$1.20
-4.76%